![\"Clascoterone](\"https:\/\/www.desouches-chirurgien-esthetique.com\/wp-content\/uploads\/2026\/02\/Clascoterone-et-Dutexome-traitements-alopecie-sans-effets-secondaires-300x201.jpg\")
<\/p>\n<\/p>\n
By 2026, the management of androgenetic alopecia will undergo a profound transformation. The focus will no longer be solely on efficacy, but also on selectivity. Increasingly informed patients will reject systemic (oral) treatments for prioritize local approaches, without impacting overall hormonal balance<\/strong>. This is the molecule that's causing a stir in the scientific and general press. Clascoterone is a topical androgen receptor antagonist. The striking figure<\/strong> According to recent phase III data reported by Midi Libre, this molecule could generate up to 539 % more hairs compared to the placebo group<\/a>.<\/p>\n Availability<\/strong> Clascoterone is not yet available in pharmacies. Marketing authorization applications are being finalized with the FDA and EMA, with availability expected in 2027. For who ?<\/strong> Men and women with early to moderate androgenetic alopecia, especially those who refuse or cannot tolerate oral treatments. For patients wishing to act immediately without waiting for marketing authorizations for new molecules, Mesoestetic's Dutexome has established itself as the reference protocol in practice.<\/p>\n This formula combines Dutasteride (0.05 %), aloe vera plant exosomes, copper tripeptide, biotin and B vitamins. Dutexome is administered by microneedling: an electric pen equipped with microneedles makes thousands of controlled micro-perforations on the scalp. For who ?<\/strong> Men and women with androgenetic alopecia, patients who have stopped or refuse oral finasteride\/dutasteride, preparation of the donor area before FUE transplantation, protection of native hair after transplantation.<\/p>\n For patients concerned about side effects on their libido or hormonal balance, these local solutions offer a credible alternative to oral treatments. Key takeaway: the earlier treatment is started, the higher the chances of stabilization. <\/em> These studies constitute the current scientific basis (2025-2026) for the use of clascoterone in androgenetic alopecia (AGA).<\/span><\/p>\n The most recent and largest studies (1,465 patients) have validated the effectiveness of the 5% solution.<\/span><\/p>\n This study determined that the concentration at 5% twice daily was the most effective compared to placebo and lower dosages.<\/span><\/p>\n Although for acne, these data confirm the systemic safety profile and the absence of impact on the hormonal axis (HPA axis).<\/span><\/p>\n An article detailing why clascoterone does not cause sexual side effects unlike finasteride.<\/span><\/p>\n Dutasteride is widely documented, although its use for alopecia is often \u201coff-label\u201d.<\/span><\/p>\n Exosomes are the new frontier of \u201ccell-free\u201d therapy.<\/span><\/p>\n The data for this specific product comes primarily from the manufacturer (Mesoestetic Pharma Group).<\/span><\/p>\n
\nTwo major developments dominate the news: Clascoterone and Dutexome<\/strong>.<\/p>\nClascoterone (Breezula): a promising prospect at +539 %<\/h2>\n
\nUnlike finasteride, which reduces DHT production throughout the body, it acts locally: it prevents DHT from attaching to the hair follicle, without ever passing through the bloodstream.<\/p>\n
\nIt is a molecule of the future, but for now it remains a clinical hope.<\/p>\n
\nAlso a possible complement to a hair transplant to stabilize native hair.<\/p>\nThe Dutexome (C.PROF 231): the solution available now<\/h2>\n
\nThis cocktail targets hair miniaturization while improving the quality of the follicular environment.<\/p>\nApplication by microneedling<\/h3>\n
\nThis technique offers a dual action: mechanical regeneration (stimulation of growth factors by the natural healing process) and transdermal passage (homogeneous penetration of active ingredients via the micro-channels created).
\nMicro-needling combined with the C.PROF 231 solution allows a large area to be treated uniformly, with an excellent tolerance profile.<\/p>\nIn summary<\/h2>\n
\n
Why these local approaches?<\/h2>\n
\nThe product works where it is applied: on the scalp.
\nThe serum concentration remains almost zero, which allows alopecia to be treated safely, whether as a preventative measure or in conjunction with a hair transplant.<\/p>\n
\nClascoterone represents the near future. <\/em>
\nDutexome via micro-needling allows action to be taken today.<\/em><\/p>\nScientific studies<\/h2>\n
Clascoterone<\/h3>\n
1. The pivotal phase III studies (SCALP-1 and SCALP-2)<\/b><\/h4>\n
\n
2. Phase IIb Study (Dose-Ranging Study)<\/b><\/h4>\n
\n
3. Safety data and FDA approval (Winlevi)<\/b><\/h4>\n
\n
4. Comparative analysis and pharmacology<\/b><\/h4>\n
\n
Dutexome \/ Dutasteride<\/h3>\n
1. Studies on Dutasteride (efficacy and safety)<\/b><\/h4>\n
\n
\n
\n
\n
2. Studies on exosomes in hair regeneration<\/b><\/h4>\n
\n
\n
\n
3. Specific documentation: c.prof 231 Dutexome<\/b><\/h4>\n
\n
\n